Kezar Life Sciences Inc (KZR) Receives Average Recommendation of “Buy” from Brokerages

Share on StockTwits

Kezar Life Sciences Inc (NASDAQ:KZR) has been given a consensus rating of “Buy” by the six analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $24.33.

A number of equities analysts have commented on the stock. William Blair restated an “outperform” rating on shares of Kezar Life Sciences in a research note on Tuesday, March 12th. Zacks Investment Research downgraded shares of Kezar Life Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th. Finally, ValuEngine downgraded shares of Kezar Life Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, December 13th.

A number of hedge funds have recently modified their holdings of the business. New York State Common Retirement Fund bought a new position in shares of Kezar Life Sciences during the fourth quarter valued at approximately $73,000. Slow Capital Inc. bought a new position in shares of Kezar Life Sciences during the fourth quarter valued at approximately $216,000. Bank of New York Mellon Corp bought a new position in shares of Kezar Life Sciences during the fourth quarter valued at approximately $411,000. Prosight Management LP boosted its stake in shares of Kezar Life Sciences by 25.5% during the third quarter. Prosight Management LP now owns 52,331 shares of the company’s stock valued at $1,120,000 after purchasing an additional 10,640 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Kezar Life Sciences by 8.7% during the fourth quarter. Northern Trust Corp now owns 56,993 shares of the company’s stock valued at $1,345,000 after purchasing an additional 4,581 shares in the last quarter. Institutional investors and hedge funds own 48.89% of the company’s stock.

Shares of KZR stock opened at $16.83 on Friday. Kezar Life Sciences has a one year low of $14.77 and a one year high of $36.33.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Further Reading: What Are Cryptocurrencies?

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SJW Group  Position Cut by Chatham Capital Group Inc.
SJW Group Position Cut by Chatham Capital Group Inc.
Talon Metals  Hits New 52-Week High at $0.16
Talon Metals Hits New 52-Week High at $0.16
Brokerages Set Nutrien Ltd  Price Target at $61.50
Brokerages Set Nutrien Ltd Price Target at $61.50
Bovis Homes Group  Earns Hold Rating from Peel Hunt
Bovis Homes Group Earns Hold Rating from Peel Hunt
Paypoint plc  Declares Dividend of GBX 21
Paypoint plc Declares Dividend of GBX 21
Telefonaktiebolaget LM Ericsson  Upgraded to Buy by Bank of America
Telefonaktiebolaget LM Ericsson Upgraded to Buy by Bank of America


© 2006-2019 Ticker Report